

LSD

Abuscreen OnLine Lysergic Acid Diethylamide

cobas[®]
Drug abuse testing

Order information

REF	CONTENT	System-ID	Analyzers on which cobas c pack can be used
20763284 122	Abuscreen OnLine Lysergic Acid Diethylamide (200 tests)	07 6328 4	COBAS INTEGRA 400 plus COBAS INTEGRA 800
20766356 122	Abuscreen OnLine LSD Calibration/Control Pack LSD Calibrator (1 × 5 mL) LSD Positive Control (2 × 4 mL) LSD Negative Control (2 × 4 mL)		

English

System information

Test LSD, test ID 0-328

Intended use

Lysergic acid diethylamide (LSD) assay is an in vitro diagnostic test for the qualitative detection of LSD and its metabolites in human urine at a cutoff concentration of 0.5 ng/mL on COBAS INTEGRA systems.

The LSD assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography or Liquid Chromatography coupled with Mass Spectrometry or Tandem Mass Spectrometry (GC/MS, GC/MS/MS, LC/MS or LC/MS/MS) is the preferred confirmatory method.^{1,2} Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

Summary

Lysergic acid diethylamide (LSD, lysergamide, Delysid) is an ergot alkaloid that is a natural product of the rye fungus *Claviceps*. However, most of the LSD consumed illicitly is derived by synthesis involving the reaction of lysergic acid with diethylamine.^{3,4} LSD is a hallucinogenic drug that can cause severe altered states of consciousness, can induce psychotic reactions characterized by hallucinations, and can cause other perceptual disturbances that mimic functional psychosis.^{4,5} LSD is thought to exert its psychotomimetic effects through antagonism of serotonin (5-hydroxytryptamine) activity in the brain stem neurons.^{4,5,6} Of the four possible synthetic diastereomers of LSD only *d*-LSD has mind altering properties. The *d*-LSD is one of the most potent hallucinogenic agents known to man, but it has a remarkably low acute toxicity.^{3,5,6} LSD is usually administered by drug abusers as the tartrate salt in oral doses of 25 to 250 µg.³ This drug undergoes such rapid and extensive metabolism that only a small fraction of a dose is excreted in human urine as unchanged LSD. Urine from suspected drug abusers contain multiple metabolites including (in order of decreasing concentration) 2-oxo-3-hydroxy-LSD, LSD-o-glucuronide, 2-oxo-LSD, LSD, N-desmethyl-LSD (nor-LSD).^{1,2,3} Although iso-LSD is not a metabolite of LSD, it is a major contaminant in many illicit LSD preparations and hence is frequently detected in the urine and other body fluids from LSD abusers.¹

Test principle

Kinetic interaction of microparticles in a solution (KIMS)^{7,8} as measured by changes in light transmission.

In the absence of sample drug, free antibody binds to drug-microparticle conjugates causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the particle-bound drug derivative for free antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.

Reagents - working solutions

Sample Diluent (SD)	Buffer containing stabilizer and 0.09 % sodium azide.
Microparticle Reagent (MP)	Conjugated LSD derivative microparticles in buffer and 0.09 % sodium azide.

Antibody Reagent (AB)

LSD antibody (goat polyclonal) in buffer and 0.09 % sodium azide.

SD is in position A, MP is in position B, and AB is in position C.

Pipetting Sequence

COBAS INTEGRA 400 plus analyzer	R1 = AB R2 = SD R3 (SR) = MP
COBAS INTEGRA 800 analyzer	R1 = SD R2 = MP R3 (SR) = AB

Precautions and warnings

Pay attention to all precautions and warnings listed in Section 1 / Introduction of this Method Manual.

For USA: For prescription use only.

Reagent handling

COBAS INTEGRA 400 plus analyzer

Mix all new (non-punctured) **cobas c** packs for 1 minute on a cassette mixer before loading on the analyzer. All in-use **cobas c** packs must also be mixed in the same manner at the beginning of each week (once a week).

COBAS INTEGRA 800 analyzer

Ready for use. After **cobas c** pack puncture, the analyzer automatically mixes the reagent for 1 minute and for half a minute during Begin of Day.

Storage and stability

Shelf life at 2-8 °C:	See expiration date on cobas c pack label
-----------------------	--

COBAS INTEGRA 400 plus analyzer

On-board in use at 10-15 °C	55 days
-----------------------------	---------

COBAS INTEGRA 800 analyzer

On-board in use at 8 °C	56 days
-------------------------	---------

Do not freeze reagents. Reagents that have been frozen should be discarded.

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Urine: Collect urine samples in clean, amber glass or non-transparent plastic containers. Fresh urine samples do not require special pretreatment, but an effort should be made to keep pipetted samples free of gross debris. As a precaution against photo decomposition of LSD, urine samples should be protected from exposure to light.¹ Samples should be within the normal physiological pH range of 5-8. No additives or preservatives are required. It is recommended that urine specimens be stored at 2-8 °C and tested within 5 days of collection.⁹

For prolonged storage, freezing of the sample is recommended.

Centrifuge highly turbid specimens before testing.

Adulteration or dilution of the sample can cause erroneous results. If adulteration is suspected, another sample should be collected. Specimen validity testing is required for specimens collected under the *Mandatory Guidelines for Federal Workplace Drug Testing Programs*.¹⁰

LSD

Abuscreen OnLine Lysergic Acid Diethylamide

Materials provided

See "Reagents – working solutions" section for reagents.

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Application for urine

COBAS INTEGRA 400 plus test definition*

Measuring mode	Absorbance
Abs. calculation mode	Endpoint
Reaction mode	R1-S-R2-SR (long test)
Reaction direction	Increase
Reaction start	SR
Wavelength A	800 nm
Test range	0-1.9 ng/mL
Postdilution factor	No
Calc. first/last	65/140
Unit	Abs.

*On COBAS INTEGRA systems, the Lab Unit is ABS, the Lab Unit Factor is 1, the Lab Unit Offset is 0, and the Decimal Position is 3.

Pipetting parameters

R1	50 µL
R2	66 µL
Sample	28 µL
R3 (SR)	40 µL
Total volume	184 µL

COBAS INTEGRA 800 test definition*

Measuring mode	Absorbance
Abs. calculation mode	Endpoint
Reaction mode	R1-S-SR-R2 (long test)
Reaction direction	Increase
Reaction start	R2
Wavelength A	629 nm
Test range	0-1.9 ng/mL
Postdilution factor	No
Calc. first/last	102/197
Unit	Abs.

*On COBAS INTEGRA systems, the Lab Unit is ABS, the Lab Unit Factor is 1, the Lab Unit Offset is 0, and the Decimal Position is 3.

Pipetting parameters

R1	65 µL
Sample	27 µL
SR	50 µL
R2	40 µL
Total volume	182 µL

Calibration

Calibrator	Abuscreen OnLine LSD Calibration/Control Pack LSD Calibrator 0.5 ng/mL (LSDST, system-ID 07 3565 5)
------------	--

Calibration mode	Cutoff
Calibration replicate	Triplicate recommended
Calibration interval	COBAS INTEGRA 400 plus analyzer: Each lot, every 14 days, and as required following quality control procedures COBAS INTEGRA 800 analyzer: Each lot, every 7 days, and as required following quality control procedures

A calibration curve is generated using the Abuscreen OnLine LSD Calibrator. This curve is retained in memory by the COBAS INTEGRA systems and recalled for later use.

Traceability: This method has been standardized against a primary reference method (LC/MS/MS).

Note

The calibrator should be assayed within 2 hours after placing on-board the instrument. Under Configuration Calibrator Definition, the STD1 value is 0.000 ABS.

Quality control

Quality control	Abuscreen OnLine LSD Calibration/Control Pack LSD Positive Control (LSDPC, system-ID 07 6534 1) LSD Negative Control (LSDNC, system-ID 07 6533 3)
-----------------	--

Control sequence	User defined
------------------	--------------

Control after calibration	Recommended
---------------------------	-------------

For quality control, use control materials as listed in the "Order information" section. In addition, other suitable control material can be used.

Drug concentrations of the controls have been verified by LC/MS/MS or GC/MS.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Note

Controls should be assayed within 2 hours of being placed on-board the instrument. The Abuscreen OnLine LSD Calibration/Control Pack is supplied as a matched set and must not be interchanged with vials from different kit lots. If control limits are utilized, they must be updated after each calibration. Update the Upper Range of the LSDPC and the Lower Range of the LSDNC to the absorbance value of the LSD CAL.

Alternatively, the controls may be run as patients. The controls should recover negative or positive, as appropriate, and the results recorded.

Results

COBAS INTEGRA systems report results with the following test flags:

Flag	COBAS INTEGRA	Value range
No flag	Negative	< 0.5 ng/mL
Positive	Positive	≥ 0.5 ng/mL

Results are reported in absorbance values relative to the 0.5 ng/mL cutoff calibrator.

Limitations - interference

See the "Specific performance data" section of this document for information on substances tested with this assay. There is the possibility that other substances and/or factors may interfere with the test and cause erroneous results (e.g., technical or procedural errors).

A preliminary positive result with this assay indicates the presence of LSD and/or its metabolites in urine. It does not measure the level of intoxication.

LSD

Abuscreen OnLine Lysergic Acid Diethylamide

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on COBAS INTEGRA analyzers. Refer to the CLEAN Method Sheet for further instructions and for the latest version of the Extra wash cycle list.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Specific performance data

Representative performance data on the COBAS INTEGRA analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined in an internal protocol by using a series of LSD controls in replicates of 20, once a day, for 5 days. The following results were obtained on a COBAS INTEGRA 700 analyzer.

Repeatability	Mean O.D.	SD	CV %
Level 1	0.950	0.02	1.8
Level 2	0.900	0.03	3.0
Level 3	0.830	0.01	1.7

Intermediate precision	Mean O.D.	SD	CV %
Level 1	0.970	0.02	1.7
Level 2	0.900	0.02	2.2
Level 3	0.830	0.01	1.4

Lower detection limit of the test

0.134 ng/mL

The lower detection limit of the COBAS INTEGRA test for LSD was determined by performing 50 replicate assays on a 0 ng/mL urine which had been previously determined to be drug free. The absorbance results were used to calculate equivalent ng/mL values as follows. A linear regression line was generated from the absorbance values of the drug free urine, the 0.5 ng/mL LSD cutoff calibrator and the 1 ng/mL LSD positive control. The absorbance values of the drug free urine were then substituted into the equation to determine the equivalent LSD concentration. The mean of 50 replicates plus 2 standard deviations yields the lower detection limit.

Accuracy

1000 assumed negative urine samples were obtained from a clinical laboratory. These samples were simultaneously evaluated for LSD using a COBAS INTEGRA 700 analyzer and the Abuscreen RIA method for LSD. 998 samples were negative and 2 samples were preliminary positive on the COBAS INTEGRA 700 analyzer. 999 samples were negative and 1 sample was preliminary positive (1.03 ng/mL) using the Abuscreen RIA method. The 1 sample that was preliminary positive in both assays was found to contain LSD by GC/MS (GC/MS value = 0.133 ng/mL).

39 urine samples, obtained from clinical laboratories where they screened preliminary positive by Abuscreen RIA and were confirmed positive for LSD by GC/MS, were also evaluated on a COBAS INTEGRA 700 analyzer. All 39 samples were positive with the COBAS INTEGRA LSD assay relative to the 0.5 ng/mL cutoff.

		RIA	
		+	-
COBAS INTEGRA 700 analyzer	+	1	1
	-	0	998

		GC/MS	
		+	-
COBAS INTEGRA 700 analyzer	+	39	0
	-	0	0

Analytical specificity

The specificity of the COBAS INTEGRA LSD assay was determined by generating inhibition curves for each of the compounds listed and determining the approximate quantity of each compound that is equivalent in assay reactivity to the 0.5 ng/mL LSD assay cutoff.

Compound	Approximate ng/mL equivalent to 0.5 ng/mL of LSD	Approximate percent cross-reactivity
Nor-LSD (N-desmethyl-LSD)	1.8	28
2-Oxo-3-hydroxy-LSD	4.4	11
Iso-LSD	11	4.5
Lysergic Acid N-(methyl-propyl) amide	16	3.1
Methysergide Maleate	3191	0.016
Ergonovine Maleate	12500	0.004
Lysergic Acid N-(hydroxy-ethyl) amide	15957	0.003
2-Bromo- α -ergocryptine	29070	0.0017
Ergotamine Tartrate	32468	0.0015
α -Lysergic acid	86207	0.0006
α -Tryptophan	116822	0.0004
Serotonin	211864	0.0002
α -Ergocryptine	750000	0.00006

Drug interference

The following compounds were added to aliquots of pooled normal human urine at a concentration of ≥ 50000 ng/mL. None of these compounds gave a positive response.

Acetaminophen	Imipramine
Acetylsalicylic acid	Isoproterenol
Aminopyrine	Ketamine
Amitriptyline	Lidocaine
Amobarbital	MDA
<i>d</i> -Amphetamine	MDMA
<i>dl</i> -Amphetamine	Melanin
<i>l</i> -Amphetamine	Meperidine
Ampicillin	Methadone
Ascorbic acid	<i>d</i> -Methamphetamine
Aspartame	<i>l</i> -Methamphetamine
Atropine	Methaqualone
Benzocaine	Methylphenidate
Benzoylcegonine	Methypylon
(cocaine metabolite)	Morphine
Benzphetamine	Naloxone
Butabarbital	Naltrexone
Caffeine	Naproxen
Calcium hypochlorite	Niacinamide
Chlordiazepoxide	Nordiazepam
Chloroquine	Norethindrone
Chlorpheniramine	<i>l</i> -Norpseudoephedrine
Chlorpromazine	Oxazepam
Cocaine	Penicillin G
Codeine	Pentobarbital

LSD

Abuscreen OnLine Lysergic Acid Diethylamide

Dextromethorphan	Phencyclidine
Dextropropoxyphene	β-Phenethylamine
Diazepam	Phenobarbital
Diphenhydramine	Phenothiazine
Diphenylhydantoin	Phenylbutazone
Dopamine	Phenylpropanolamine
Doxylamine	d-Phenylpropanolamine
Ecgonine	d,l-Phenylpropanolamine
Ecgonine methyl ester	Procaine
Ephedrine	Promethazine
d-Ephedrine	d-Pseudoephedrine
l-Ephedrine	l-Pseudoephedrine
Epinephrine	Quinidine
Erythromycin	Quinine
Estriol	Secobarbital
Fenoprofen	Sulindac
Furosemide	Tetracycline
Gentisic acid	Δ ⁹ THC-9-carboxylic acid
Glutethimide	Tetrahydrozoline
Guaiacol glycerol ether	Trifluoperazine
Hydrochlorothiazide	Tyramine
p-Hydroxyamphetamine	Verapamil
Ibuprofen	

Any modification of the instrument as set forth in this labeling requires validation by the laboratory.




References

- 1 Reuschel SA, Eades D, Foltz RL. Recent advances in chromatographic and mass spectrometric methods for determination of LSD and its metabolites in physiological specimens. J Chromatogr B Biomed Sci Appl 1999;733(1-2):145-159.
- 2 Poch GK, Klette KL, Hallare DA, et al. Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD. J Chromatogr B Biomed Sci Appl 1999;724(1):23-33.
- 3 Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 7th ed. Foster City, CA: Biomedical Publications 2004.
- 4 Caldwell J, Sever P. The biochemical pharmacology of abused drugs: Amphetamine, Cocaine, and LSD. Clin Pharmacol Ther 1974;16(4):625-638.
- 5 Hardman JG, Limbird LE, Gilman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw Hill Pub Co. 2001.
- 6 Boakes RJ, Bradley PB, Briggs I, et al. Antagonism of 5-hydroxytryptamine by LSD-25 in the central nervous system: a possible neuronal basis for the actions of LSD-25. Br J Pharmacol 1970;40(2):202-218.
- 7 McNally AJ, Goc-Szkutnicka K, Li Z, et al. An OnLine immunoassay for LSD: comparison with GC-MS and the Abuscreen RIA. J Anal Toxicol 1996;20(6):404-408.
- 8 Armbruster DA, Schwarzhoff RH, Pierce BL, et al. Method comparison of EMIT II and ONLINE with RIA for drug screening. J Forensic Sci 1993 Nov;38(6):1326-41.
- 9 Toxicology and Drug Testing in the Clinical Laboratory; Approved Guideline. 2nd ed. (C52-A2). Clinical and Laboratory Standards Institute 2007;27:33.
- 10 Mandatory Guidelines for Federal Workplace Drug Testing Programs. Fed Regist 2008 Nov 25;73:71858-71907.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard:

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS C, COBAS INTEGRA and ABUSCREEN are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2016, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336

